Abstract Background An increasing number of patients survive their early breast cancer (EBC) but may experience longer term impact on their quality of life (QoL) arising from their diagnosis and treatment. Survivors are also at risk of other possibly life-shortening chronic diseases due to concomitant risk factors (smoking, drinking >14 units of alcohol/week, and low exercise levels). Little is known about the lifestyle factors and long-term challenges facing EBC survivors. We report the initial results of a questionnaire (containing patient-reported outcomes measures (PROMS), and lifestyle factor questions) completed by EBC survivors at the Royal Marsden hospital (RMH), UK. Methods We prospectively identified a patient cohort of patients (October 2021 to June 2022) with stage I-III EBC who had completed their curative treatment (endocrine treatment (ET) may be ongoing) and who were attending for their annual surveillance breast imaging at years 1, 2, 4, and >5 years. Patients completed PROMS (using EORTC (European Organisation for Research and Treatment of Cancer) QLQ-SURV100 and -BR23) and questionnaires regarding smoking, alcohol, and exercise levels (via the International Physical Activity Questionnaire (IPAQ)). Patient, clinical, disease and treatment characteristics were recorded and the EORTC and IPAQ questionnaires were analysed according to the EORTC and IPAQ analysis manuals. Results Data are available for 187 women at the time of this analysis (it is anticipated data will be available for 350 at the time of SABCS 2022). Patients were attending for their year 1 (N=66, 35.3%), 2 (N=43, 23%), 4 (N=43), or >5 years (N=35, 18.7%) imaging post-surgery. 62 (86.6%) patients were Eastern Cooperative Oncology Group Performance Status 0-1, and 31 (16.6%) had >2 of other comorbidities. 123 patients (65.8%) were post-, 16 (8.6%) peri-, and 48 (25.7%) premenopausal. 178 (95.2%) underwent primary surgery. Of those patients undergoing surgery, 19 (10.2%) had a mastectomy, and 168 (89.8%) breast conserving surgery. All patients had axillary surgery: 26 (13.9%) axillary dissection, and 158 (84.5%) sentinel lymph node biopsy. 166 patients (88.8%) received adjuvant ET and for most patients (N= 149, 79.7%) this was ongoing at time of analysis. 31.6% (N= 59) had prior exposure to cardiotoxic treatment. Risk groups for other chronic health conditions could be identified: 92 (49.2%) patients had a BMI of >25, 5 (4.2%) were current smokers, and 16 (13.6%) were classified as at-risk drinking. Patients reported that their physical function was affected following their diagnosis and treatment, with 51 (27.3%) having trouble running short distances and 52 (27.8%) taking a long walk carrying a heavy backpack. Nonetheless all patients (N=118 available for IPAQ analysis) had moderate (N=61, 51.7%), or high-level (N= 58, 49.2%) levels of exercise. 85 patients (45.5%) had pain in the past week, and 101 patients (54%) were dissatisfied with the appearance of their body. Most patients (N=152, 81.3%) estimated their overall QoL in the last week as very good (5-7) (scale 1-7, with 7 being excellent). QLQ-BR23 symptom scales were compared between patient groups. Patients who had chemotherapy suffered ongoing from hair loss (52.6% vs 45.2%) than chemo-naïve patients. There were no major differences between groups who received ET and those ET naïve. Conclusions We were able to identify groups of patients at risk for other comorbidities and cancers. We could also highlight groups of EBC survivors with a higher level of QoL concerns. PROMS should be routinely assessed in EBC survivors to better address subgroups at higher risk, inform consultations, and treatment decisions. Citation Format: Jasmin V Waterhouse, Jasmine Pattarukuzhyil Jose, Nikki Snuggs, Annette White, Kate Harper, Marieke van Leeuwen, Alistair Ring. Lifestyle factors and patient-reported outcome measures using the European Organisation for Research and Treatment of Cancer survivorship questionnaire in early breast cancer patients attending for surveillance imaging [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P5-08-12.
Read full abstract